Michael Sun1, Muhammad Junaid Niaz2, Muhammad Obaid Niaz3, Scott T Tagawa4,5,6. 1. Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, 525 East 68th Street, Box 403, New York, NY, 10065, USA. 2. Department of Urology, Weill Cornell Medicine, New York, NY, USA. 3. Sharif Medical City Hospital, Lahore, Pakistan. 4. Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, 525 East 68th Street, Box 403, New York, NY, 10065, USA. stt2007@med.cornell.edu. 5. Department of Urology, Weill Cornell Medicine, New York, NY, USA. stt2007@med.cornell.edu. 6. Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. stt2007@med.cornell.edu.
Abstract
PURPOSE OF REVIEW: Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) is a promising investigational treatment for metastatic castration-resistant prostate cancer (mCRPC). This review describes the available data with PSMA TRT. RECENT FINDINGS: Conjugates used for PSMA TRT include antibodies or small molecules PSMA-radiolabeled with beta (most commonly 177Lu) or alpha emitters (commonly 225Ac). 177Lu-J591 demonstrated accurate targeting of known metastatic sites, based on post-treatment scintigraphy, in study populations that were not selected for PSMA expression, with evidence of dose-response and dose-limiting myelosuppression. Early phase studies of 177Lu-PSMA-617 have demonstrated favorable adverse event profiles and signs of clinical activity as evidenced by PSA responses and other short-term outcomes. A phase II randomized study of 177Lu-PSMA-617 showed a superior PSA50 response rate (66 vs 37%) over cabazitaxel in patients with docetaxel-pretreated, progressive mCRPC selected by PSMA and FDG PET/CT scans. PSMA TRT is emerging as a promising investigational therapy for mCRPC. The first randomized data with 177Lu-PSMA-617 (phase 2) have been presented, and the first phase 3 trial has completed accrual with radiographic progression-free and overall survival as dual primary endpoints. Multiple additional phase 3 trials of PSMA-TRT are starting and studies investigating optimal patient selection and combination therapy continue.
PURPOSE OF REVIEW: Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) is a promising investigational treatment for metastatic castration-resistant prostate cancer (mCRPC). This review describes the available data with PSMA TRT. RECENT FINDINGS: Conjugates used for PSMA TRT include antibodies or small molecules PSMA-radiolabeled with beta (most commonly 177Lu) or alpha emitters (commonly 225Ac). 177Lu-J591 demonstrated accurate targeting of known metastatic sites, based on post-treatment scintigraphy, in study populations that were not selected for PSMA expression, with evidence of dose-response and dose-limiting myelosuppression. Early phase studies of 177Lu-PSMA-617 have demonstrated favorable adverse event profiles and signs of clinical activity as evidenced by PSA responses and other short-term outcomes. A phase II randomized study of 177Lu-PSMA-617 showed a superior PSA50 response rate (66 vs 37%) over cabazitaxel in patients with docetaxel-pretreated, progressive mCRPC selected by PSMA and FDG PET/CT scans. PSMA TRT is emerging as a promising investigational therapy for mCRPC. The first randomized data with 177Lu-PSMA-617 (phase 2) have been presented, and the first phase 3 trial has completed accrual with radiographic progression-free and overall survival as dual primary endpoints. Multiple additional phase 3 trials of PSMA-TRT are starting and studies investigating optimal patient selection and combination therapy continue.
Entities:
Keywords:
Metastatic castration resistant prostate cancer; Monoclonal antibodies; Prostate specific membrane antigen; Radioligand therapy; Small molecules; Targeted therapies
Authors: Neeta Pandit-Taskar; Joseph A O'Donoghue; Jeremy C Durack; Serge K Lyashchenko; Sarah M Cheal; Volkan Beylergil; Robert A Lefkowitz; Jorge A Carrasquillo; Danny F Martinez; Alex Mak Fung; Stephen B Solomon; Mithat Gönen; Glenn Heller; Massimo Loda; David M Nanus; Scott T Tagawa; Jarett L Feldman; Joseph R Osborne; Jason S Lewis; Victor E Reuter; Wolfgang A Weber; Neil H Bander; Howard I Scher; Steven M Larson; Michael J Morris Journal: Clin Cancer Res Date: 2015-07-14 Impact factor: 12.531
Authors: Michael S Hofman; Louise Emmett; John Violet; Alison Y Zhang; Nicola J Lawrence; Martin Stockler; Roslyn J Francis; Amir Iravani; Scott Williams; Arun Azad; Andrew Martin; Margaret McJannett; Ian D Davis Journal: BJU Int Date: 2019-10-22 Impact factor: 5.588
Authors: Clemens Kratochwil; Frederik L Giesel; Melsa Stefanova; Martina Benešová; Marcus Bronzel; Ali Afshar-Oromieh; Walter Mier; Matthias Eder; Klaus Kopka; Uwe Haberkorn Journal: J Nucl Med Date: 2016-03-16 Impact factor: 10.057
Authors: Gail J Roboz; John M Bennett; Morton Coleman; Ellen K Ritchie; Richard R Furman; Adrianna Rossi; Komal Jhaveri; Eric J Feldman; John P Leonard Journal: Leuk Res Date: 2007-05-01 Impact factor: 3.156
Authors: Stefanie Hammer; Urs B Hagemann; Sabine Zitzmann-Kolbe; Aasmund Larsen; Christine Ellingsen; Solene Geraudie; Derek Grant; Baard Indrevoll; Roger Smeets; Oliver von Ahsen; Alexander Kristian; Pascale Lejeune; Hartwig Hennekes; Jenny Karlsson; Roger M Bjerke; Olav B Ryan; Alan S Cuthbertson; Dominik Mumberg Journal: Clin Cancer Res Date: 2019-12-12 Impact factor: 12.531
Authors: Johanna Maffey-Steffan; Lorenza Scarpa; Anna Svirydenka; Bernhard Nilica; Christian Mair; Sabine Buxbaum; Jasmin Bektic; Elisabeth von Guggenberg; Christian Uprimny; Wolfgang Horninger; Irene Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2019-11-27 Impact factor: 9.236
Authors: Scott T Tagawa; Naveed H Akhtar; Anastasia Nikolopoulou; Gurveen Kaur; Brian Robinson; Renee Kahn; Shankar Vallabhajosula; Stanley J Goldsmith; David M Nanus; Neil H Bander Journal: Front Oncol Date: 2013-08-26 Impact factor: 6.244